However, these results were not consistent across all the CVOTs regarding GLP-1RAs, and the pooled meta-analysis of CVOTs (the LEADER, SUSTAIN‐6, REWIND, HARMONY, ELIXA, and PIONEER trials) showed no significant differences in the risk of incident AF between GLP1‐RA and placebo among participants with type 2 diabetes (OR 0.93; 95% CI 0.70–1.23; I2 = 58%) [28]. Here, GLP1R is linked to atrial fibrillation.